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LETTER TO THE EDITOR
New MIBG preparation to improve targeted radiotherapy and reduce
toxic side-effects in neuroblastoma patients undergoing combination
treatment
Sir - A recent study of cancer patients undergoing cytotoxic
drug treatment has strongly implicated noradrenaline as a
potentiator of the delayed nausea and vomiting response
(Fredrikson et al., 1994). Specific receptors for noradrenaline
would appear to be involved since a correlation between
post-chemotherapy nausea and levels of noradrenaline, but
not adrenaline, was observed. It is worth noting that these
findings, and those reported previously showing that
catecholamines can up-regulate nausea and vomiting (And-
rews et al., 1988; Leslie and Reynolds, 1993), could have
important implications in another approach to cancer treat-
ment.
Targeted radiotherapy using meta-["'Oiodobenzylguanidine
(MIBG) is a promising treatment for neuroblastoma and
other neuroendocrine tumours. This radiopharmaceutical is
accumulated in tumour via the noradrenaline transporter.
Since a therapeutic dose of ['31I]MIBG (7.4-14.8 GBq) con-
tains 7-14 mg of this biogenic amine, the relationship
between noradrenaline and nausea observed by Fredrikson et
al. (1994) might unfortunately be relevant. Indeed, the
administration of therapeutic doses of MIBG has been
associated with nausea (Shapiro and Fischer, 1985).
Currently, a UKCCSG-coordinated study is being planned
which will examine the efficacy of [3'I]MIBG for the treat-
ment of neuroblastoma in combination with chemotherapy.
Since chemotherapeutic agents themselves induce nausea and
vomiting, it is possible that the noradrenaline receptor ligand
MIBG may aggravate this disturbing response in patients
undergoing combined-modality therapy.
We would like to point out that it should be possible to
perform targeted radiotherapy using MIBG without this
potential side-effect by exploiting recent developments in the
radiolabelling of this molecule. Commercially available
['31I]MIBG, synthesised from cold MIBG by an iodine
exchange reaction, results in a product in which only 1 in
2000 MLBG molecules is radioactive. In contrast,
radioiodesilylation (Vaidyanathan and Zalutsky, 1993) pro-
duces no-carrier-added (n.c.a.) ['31I]MIBG which is essentially
free from contaminating non-radiolabelled MIBG. As a
result, a therapy dose would contain only a few micrograms
of drug, which should minimise potential nausea and
vomiting side-effects.
Use of the n.c.a. preparation would be expected to yield a
number of additional benefits. First, therapeutic-level doses
of commercially available ['1I]MIBG can cause an elevation
of blood pressure, necessitating slow infusion of the drug
over 2 h. By decreasing the amount of MIBG administered,
these pressor effects should be drastically reduced. Recent in
vitro and in vivo studies have documented that the n.c.a.
[1311]MIBG preparation could be a more effective agent than
the conventional preparation (Mairs et al., 1994). The n.c.a.
preparation is both more toxic to neuroblastoma cells in
culture and exhibits greater uptake in human neuroblastoma
xenografts than the iodine exchange preparation.
We are currently investigating whether such advantages
will also exist in patients. However, even if tumour targeting
of n.c.a. MIBG was the same as that of the standard
preparation, we believe that the potential lack of side-effects
with n.c.a. ['31I]MIBG is sufficient rationale for the use of this
radiopharmaceutical. We hope that the radiopharmaceutical
industry will consider producing n.c.a. ['31I]MIBG despite the
relatively small numbers of patients treated with this agent.
Yours etc,
Rob J Mairs
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